R1 Therapeutics Raises $80.5 Million in Series A Funding
R1 Therapeutics, a biopharmaceutical company based in Redwood City, California, has successfully secured $80.5 million in a Series A funding round. The company is focused on developing innovative therapies for patients suffering from kidney disease, aiming to redefine treatment protocols in this area.
Lead Investor and Participants
The funding round was led by Samsara BioCapital, a prominent investor in the biotech sector. Other participants in the round include Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital, and U.S. Renal Care.
Use of Funds
The newly raised funds will be directed towards the advancement of R1 Therapeutics' lead asset, AP306. This first-in-class pan phosphate transporter inhibitor is being developed as a monotherapy for hyperphosphatemia in patients undergoing dialysis. The company plans to use the capital to support the ongoing global Phase 2b trial, with topline data expected in the first half of 2027.
Leadership Insights
Krishna Polu, M.D., co-founder, president, and CEO of R1 Therapeutics, commented on the investment, highlighting the strategic value Samsara BioCapital brings to the company. "Samsara brings a rare combination of scientific depth and a track record of investing in kidney companies across the private and public markets," he said.
Looking Ahead
With this significant financial boost, R1 Therapeutics is well-positioned to continue its work on AP306 and potentially bring new treatment options to patients with chronic kidney disease. The company's efforts are watched closely by stakeholders in the healthcare and biotech sectors, as they work towards unveiling the Phase 2b trial results in 2027.